# Attachment 4

Data Collection Instrument

OMB Control No. 0920-xxxx Expiration Date: xx/xx/xxxx

#### Physicians' Practices Regarding Prostate Cancer Screening

The Centers for Disease Control and Prevention (CDC) is inviting you to participate in a national survey of physicians being conducted for CDC by the Battelle Centers for Public Health Research and Evaluation.

CDC is interested in your practices and opinions regarding prostate cancer screening. Your opinions will guide CDC and other organizations that develop new clinical training materials, clinical decision support tools, and materials physicians use to counsel and educate patients. Therefore, the input of practicing physicians is very important.

This survey includes questions about your demographic, practice and patient characteristics. Then, we ask about your practices and opinions about prostate cancer screening. Finally, we seek your opinions about your management of prostate-specific antigen (PSA) screening for prostate cancer in your practice under various clinical scenarios.

The survey asks your opinions about a range of PSA screening practices and screening guideline information that has changed rapidly over the last few years and includes questions about practices that may not be the standard of care in your community or may not be endorsed by clinical guidelines.

- 3,000 randomly selected primary care physicians have been sent this survey. We need the response of every physician to make this important study valid and representative of diverse practice styles of U.S. primary care physicians.
- > Your responses will be treated in a **secure** manner.
- Battelle must maintain the link between names and participant ID numbers for tracking survey mailings. While Battelle will have the capability to link responses to individual participants, this capability will only be present until data collection is completed. At that point, the tracking file will be destroyed and there will be no way to link responses to you.
- > Survey reports will present all findings in aggregate so individual responses cannot be identified.
- > On average, the survey will take about 30 minutes to complete.
- > Some questions about your provision of advice to patients about prostate cancer screening, or about your practices that may differ from institutional clinical practice recommendations may cause you discomfort.
- Your participation in this survey is voluntary. You may choose to withdraw from the study or to skip any questions that you do not want to answer.

Public reporting burden of this collection of information varies from 20 to 40 minutes with an estimated average of 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-XXXXX)

## Section I: Physician and Practice Characteristics

This part of the survey asks questions that will let us describe the participants who respond to the survey. Please write in or check ( $\checkmark$ ) the best answer.

1.	What is your age?
2.	What is your sex? ☐ Male ☐ Female
3.	Are you of Hispanic or Latino origin? ☐ Yes ☐ No
4.	What is your race or racial heritage? Check all that apply.  ☐ American Indian or Alaska Native ☐ Native Hawaiian or other Pacific Islander ☐ White  ☐ Black or African American
5.	What year did you graduate from medical school?(enter year)
6.	Since completing your medical training (including residency and fellowship), how long have you been practicing medicine?Years
7.	Where did you complete your residency training?(enter state).
	☐ Not applicable, I did not complete residency training
8.	What is your primary clinical specialty? (Please ✓only one)  □ Family Practice □ General Practice □ Internal Medicine
	□ Other(Please specify)
9.	What is your clinical sub-specialty, if any?(Please specify)
10.	Do you currently (last 2 months) practice in an outpatient setting?
	☐ Yes —— Continue
	☐ No STOP and return the survey at this point

Please answer the remainder of the survey based on your "primary practice site," the location where you spend most of your outpatient care practice time.

11. On average, how many hours per week do yo practice site?	ou spend on direct patient care at your primary
Average number of hours per week	
If you spend less than 8 hours per site, please STOP and return the survey in the	
12. Do you provide health maintenance exams to	any of your patients at this site?
☐ Yes (Continue with the survey)	□ No
If you do not provide health mainte to any of your patients at this site, the postage-paid envelope.	
Please answer the remainder of the questionnaire abo	out your <b>Primary Practice Site.</b>
13. Where is this practice located? Is it within a(a	an): <b>(Please ✓ only one)</b>
☐ Private practice office	☐ Hospital emergency department
Ambulatory care clinic of hospital/medical center	☐ Institutional setting/clinic (e.g., correctional, nursing home)
☐ Urgent care clinic	☐ Clinic that is part of a Health Maintenance Organization
☐ Community health center	☐ Academic or teaching hospital
<ul><li>☐ Public health clinic</li><li>☐ Other type of</li></ul>	
clinic(specify)	
14. Is this practice a: (Please ✓ only one)	
☐ Solo practice?	
☐ Single-specialty group practice?	
☐ Multi-specialty group practice?	
☐ Other type of practice (please specify)	?

15.	Does your practice pa (Please ✓ all that ap		y of the following types of Managed Care Contracts (MCO)?
	☐ Staff-model HMO (	(e.g., Kaiser)	
	☐ Group-model HMC	)	
	☐ Network-model HM	ЛО (e.g., need	an example)
	☐ Independent-Pract	ice Associatio	n (IPA)
	☐ Preferred Provider	Organization	(PPO)
	☐ Point-of-Service PI	lan (POS)	
	☐ Other type of MCC	) (please spec	ify)?
16.	Zip code of this praction	ce (first 5 digit	s only):
17.	Please indicate which primary practice is loc		ng best describes the size of the community in which your <b>only one</b> )
	☐ A community of fo	ewer than 2,50	00 people
	☐ Small town of 2,5	501 to 10,000	people
	☐ Medium-sized tove people	wn of 10,001 t	o 25,000
	☐ Large town of 25	,001 to 50,000	) people
	☐ A small city of 50	,001 to 100,00	00 people
	☐ City of 100,001 to	250,000 peo	ple
	☐ Large city of 250,	,000+ people	
18.	Please indicate which practice is located (Pl		ng best describes the community setting in which your primary one)
	☐ Rural		
	☐ Suburban		
	Urban	☐ Inner city	
		☐ Not inner	
	city		
10	Do you practice in a fe	adorally qualif	ied health manpower shortage area?
TA.	Do you practice in a R	cucially qualli	eu neam manpower shortage alea?
	☐ Yes ☐ N	No	☐ Don't know

#### Section II: Patient Characteristics

Please give us your best estimates for the following questions about characteristics of the patients you see in your primary practice site. Please write in or check ( $\checkmark$ ) your response. Your <u>best estimate</u> is all we need.

1.	On average, how many patients do you see in a typical week?						
2.	Approximately what <b>percent</b> of your patients are <b>male</b> ? %						
3.	Approximately what <b>percent</b> of your <b>male</b> patients are over age	40?%					
4.	How many health maintenance exams do you perform on male	s over age 40 per week?					
5.	Approximately what <b>percent</b> of your <b>male</b> patients are:						
	White%						
	Black, African or African American %						
	Native American or Alaska Native%						
	Asian%						
	Native Hawaiian or Pacific Islander %						
	Other (including multiracial) % TOTAL 100%						
6.	Approximately what <b>percent</b> of your <b>male</b> patients are of						
	Hispanic or Latino origin %						
7.	Please estimate what percentage of your patients use the follow	ving primary payment methods:					
	Self pay	%					
	Private Managed Care (HMO, MCO, PPO, IPA, POS)	%					
	Other private medical insurance	%					
	Medicaid, including Medicaid Managed Care	%					
	Medicare, including Medicare Managed Care	%					
	Other Government (e.g., CHAMPUS, HRSA)	%					
	Charity care (no fee charged)	%					
	Other insurance type or payor (specify) Total	100% %					

### Section III: Clinical Practice

Please provide the following answers based on your **routine practices** during health maintenance exams (HME) with **male patients 40 and older**.

Prostate Cancer Screening Practices

1.	their HME?	· ·	mination (DRE) on asymptomatic patients as	part of	
	☐ Yes	☐ No (If NO, Go to	o Question 8)		
2.	What percent of your	patients visiting for an	HME do you offer DRE?	%	
3.	What percent of your	HME patients get DRE	E?%		
4.	Please check the rea	son you perform DRE	? (Please ✓ all that apply)		
	☐ To get an in-office	nd rectum for abnorm e specimen for FOB1		(Please	
5.			RE to the following types of patients? <b>If you</b>		
	patients".	er DRE for such patie	ents, please check (✔) "I do not offer DRE	to these	
		·			I do not offer DRE to these patients
	patients".	Type of P	Patient	Age	offer DRE to these patients
	patients".  Asymptomatic White n Asymptomatic White n	Type of Pnalesnales with a family histo	Patient  Dry of prostate cancer		offer DRE to these
	patients".  Asymptomatic White n Asymptomatic White n Asymptomatic African	Type of P nalesnales with a family histo American males	Patient  Dry of prostate cancer		offer DRE to these patients
	patients".  Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African	Type of Pnalesnales with a family histo American males American males with a	Patient  Dry of prostate cancer		offer DRE to these patients
	patients".  Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African Asymptomatic Asian A	Type of Pnalesnales with a family histon American males	Patient  Dry of prostate cancer  a family history of prostate cancer.		offer DRE to these patients
	patients".  Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African Asymptomatic Asian A Asymptomatic Asian A	Type of P nales nales with a family histo American males American males with a merican males with a f	Patient  ory of prostate cancer  a family history of prostate cancer.  family history of prostate cancer		offer DRE to these patients
	Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African Asymptomatic Asian A Asymptomatic Hispani	Type of P nales nales with a family histo American males American males with a merican males with a f c or Latino males	Patient  ory of prostate cancer  a family history of prostate cancer.  family history of prostate cancer		offer DRE to these patients
	Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African Asymptomatic Asian A Asymptomatic Hispani Asymptomatic Hispani	Type of P nales nales with a family histo American males with a American males with a merican males with a f c or Latino males with a c or Latino males with a	Patient  Ory of prostate cancer  Is family history of prostate cancer  family history of prostate cancer  a family history of prostate cancer	Age	offer DRE to these patients
	Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African Asymptomatic Asian A Asymptomatic Hispani Asymptomatic Hispani Asymptomatic Native A	Type of P nales nales with a family histo American males with a merican males with a f c or Latino males with a c or Latino males with a	Patient  Ory of prostate cancer  Is family history of prostate cancer  family history of prostate cancer  a family history of prostate cancer		offer DRE to these patients
	Asymptomatic White n Asymptomatic White n Asymptomatic African Asymptomatic African Asymptomatic Asian A Asymptomatic Hispani Asymptomatic Hispani Asymptomatic Native A	Type of P nales nales with a family histo American males with a merican males with a merican males with a c or Latino males with a American or Alaskan m	Patient  Dry of prostate cancer  A family history of prostate cancer  family history of prostate cancer  a family history of prostate cancer  a family history of prostate cancer nales	Age	offer DRE to these patients

	Please specify why you stop performing routine DRE? (Please ✓ all that apply)	
l	Reasons for discontinuing DRE	
	Advanced age	
	<ul><li>Existing co-morbid conditions.</li><li>Debilitated health status.</li></ul>	
	Debilitated health status	
8.	Do you routinely offer Prostate Specific Antigen (PSA) testing for asymptomatic male patients as part of their HME?	
	☐ Yes ☐ No	
	Why not? ☐ Organizational practice policy	
	☐ National guidelines do not support offering	
	☐ Insufficient evidence to demonstrate impact on mortality	
	☐ Other (Please	
specify)		
	Go to Question 21	
9.	What percent of your male patients visiting for an HME are offered PSA?	)
10.	What percent of your HME patients receive PSA?%	
11	Relative to the DRE, when do you routinely draw blood for PSA?	
routine I	☐ Before DRE ☐ After DRE ☐ Both before and after DRE ☐ I do not do	
12.	At what age do you begin to routinely offer the PSA test to the following types of patients? If you do not see such patients or offer PSA for such patients, please check (✓) "I do not offer PSA to these patients".	
	Type of PatientAge	I do not offer PSA to these patients
	Asymptomatic White males	
	Asymptomatic White males with a family history of prostate cancer	
	Asymptomatic African American males	
	Asymptomatic African American males with a family history of prostate cancer.  Asymptomatic Asian American males	
	Asymptomatic Asian American males with a family history of prostate cancer	
	Asymptomatic Hispanic or Latino males	
	Asymptomatic Hispanic or Latino males with a family history of prostate cancer	
	Asymptomatic Native American or Alaskan males Asymptomatic Native American or Alaskan males with a family history of prostate cancer	
	Asymptomatic inalive American of Alaskan males with a family history of prostate cancer	
13.	Do you ever stop offering routine PSA to asymptomatic patients?	

	☐ Yes (If YE	S, Go to Qu	estion 14)	☐ No (I	f NO, Go to Q	uestion 15)		
14.	Please specif	y why you sto	op offering PSA? (Plea	ase ✔ all tha	t apply)			
F	Reasons for d	iscontinuing	j PSA					
		Advanced	age					
			-morbid conditions					
		Debilitated	health status					
15.	•	of PSA tests	you order are perform	ed on men w	no are asympt	omatic?		
16.	What percent urinary tract s		you order are perform %	ied on men wl	no experience	non-specific lo	wer	
17.	What percent	of your patie	nts are screened for p	rostate cance	r under the foll	owing condition	ns?	
			Type of Patient			%		
			(HME)					
			up other than HME (e.զ		•			
	•							
	Other							
18.	How often do	you screen f	or prostate cancer in y	our asympton	natic male pati	ents?		
	Once a ye	ear						
	☐ Every two	years						
	☐ When the	patient com	es in for a periodic H	IME				
		-	_(Please specify)					
19.	How often do African Ameri		or prostate cancer in y tients?	our high risk (	e.g., patients \	with a family his	story or	
	☐ Once a ye	, ,						
	☐ Every two							
	•	•	es in for a periodic H	IME				
		patront com	_(Please specify)					
	<b>—</b> Other		_(r rease speemy)					
20.	If a PSA is highe	er than the expec	ted normal range, what do y	ou generally do	next?			
				Never	Sometimes	Half the time	Usually	Always
a.	Repeat the Pa	SA test						
b.		•	(e.g., complex PSA)					
_			ions					
		-						
e.	Check for infe	ection						

21.	Please indicate how often you do any of the followi	ing				
	_	Never	Sometimes	Half the time	Usually	Always
a.	Provide written information (i.e., pamphlets, guides), videos, or other educational materials on PSA screening in your office or clinic for					
	patients to browse or take home					
	Refer patients to any type of educational materials about prostate cancer screening					
	Screen men age 75 and older who have no significant health or medical problems					
a.	Screen men with significant co-morbid conditions					
23.	Do you routinely discuss prostate cancer screening the decision about screening? (Please check (✓)  Yes, with all patients  Yes, with patients who decline the test  Yes, with patients who had a previous elevate Yes, with patients who request PSA test  No (If NO, Go to Question 26)  What is your usual policy when discussing PSA test	only one) ed PSA		o involve the p	duent III	
	☐ I try to talk the patient into getting the test☐ I try to talk the patient out of getting the test☐ I remain neutral☐ ☐ I remain neutral☐ ☐ ☐ I try to talk the patient out of getting the test☐ ☐ ☐ I remain neutral☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐					
24.	At what age do you begin discussing prostate cancer with these patients.					
	Type of Patient				Age	I do not discuss with these patients
	Asymptomatic White males			_	7190	
	Asymptomatic White males with a family history of					_
	Asymptomatic African American males					
	Asymptomatic African American males with a famil					
	Asymptomatic Asian American males Asymptomatic Asian American males with a family					
	Asymptomatic Hispanic or Latino males					
	Asymptomatic Hispanic or Latino males with a fam	ily history o	f prostate cand	er		
	Asymptomatic Native American or Alaskan males Asymptomatic Native American or Alaskan males					
25.	Approximately how much time is usually involved in	n the discus	sion?	minu	tes.	

26.	Do y	ou require an inform	ned consent prior to pe	rforming a P	SA test for	screening p	ourposes?		
	_ _	Yes, verbal conse Yes, written conse No							
27.	Have	-	med or shared decision ☐ No (If NO, Go to Q	_					
28.	Have	•	informed or shared dec ☐ No (If NO, Go to Q	J		oractice?			
29. Have you been satisfied with the results? ☐ Yes ☐ No									
30.	In ge one)		whether a patient shou	ıld have pros	state cance	er testing <b>(P</b>	lease <b>√</b> onl	у	
	I decid	de							
	I most	ly decide							
			he patient and/or his	family mem	her(s)				
		J	•	•	DC1(3)				
			family member(s) mos	sily decides					
Ц	The p	atient and/or family	member(s) decides						
Scre	<u>enin</u>	g Efficacy a	<u>nd Beliets</u>						
Please	check	( <b>√)</b> how strongly y	ou agree or disagree w	rith each stat	ement belo	OW.			
1. My p	erform	ning <b>Digital Rectal</b>	Exam in average risk	oatients:					
a.	Perm	its me to use a reli	able tool for cancer det	ection	Strongly Disagree	Disagree	Neither	Agree	Strongly Agree
b.	treatr	nent of prostate ca	rough early detection a						
c. d.			armnalpractice claims		Ö		Ö	ä	ä
e.			nbursement						
f.	Is un	wanted by most of	my male patients						
g.			about the meaning of t						
h.			racies (e.g. false positiv barrassment or discom		ū		ā	ā	ū
i.	Is dif	icult due to patient	embarrassment or disc	comfort					
j.			natient does not perceiv						Ц
1.			ealth threat						

	Strongly Agree
k. Is difficult due to patient's beliefs that screening is not effective	
I. Is difficult due to patient fears of potential side effects of treatment	
m. Is difficult due to my belief that screening is not effective n. Is difficult due to patient myths and misconceptions	
o. Is difficult due to a lack of scientific evidence of survival benefit	
p. Is difficult due to a lack of consensus regarding DRE $\square$ $\square$ $\square$	
screening guidelinesq. Allows me to assess other health problems (CRC,	
hemorrhoids, etc)	
patients age 50 years and olders. Is difficult due to patient cultural barriers	
t. Is difficult due to a lack of confidence in my DRE skills	
My discussing prostate cancer screening:	
Strongly  Disagree Disagree Neither Agree	Strongly Agree
a. Is helpful because my male patients need to be	
b. Is easy because I feel confident I know enough about the	
benefits of screening to give patients adequate information	
c. Is easy because I feel confident I know enough about the possible risks of screening outcomes to give patients	
adequate information regarding prostate cancer	_
d. Is something most patients are comfortable making an informed decision about screening	
e. Does not allow me the time to discuss the advantages/disadvantages of screening	
f. Results in lack of or low reimbursement	Ē
g. Is too complex to cover in a limited amount of time	
i. Is challenging because patients are unwilling to discuss	
j. Is challenging because patients are not interested in topic  k. Is difficult due to patient cultural or language barriers	
k. Is difficult due to patient cultural or language barriers	Ö
understand	
The disconnectable for patients	_
3. My providing PSA testing to average risk patients:  Strongly	Strongly
a. Permits me to use a reliable tool for cancer detection	Agree
b. Helps men live longer through early detection and treatment of prostate cancer	
c. Does more good than harm	ū
d. Helps protect me from malpractice claims	
e. Results in lack of or low reimbursement	

		Strongly Disagree	Disagree	Neither	Agree	Strongly Agree	
g.	Coincides with the standard of care in my community	Disagree	Disagree	Neither	Agree	Agree	
h.	Will result in the uncertainty about the meaning of the						
i.	test result (false positives?)	ō	ā	ō		ū	
j.	Is difficult due to patient not perceiving prostate cancer to	_	_	_		_	
	be a serious health threat						
k.	Is difficult due to patient beliefs that screening is not effective						
l.	Is difficult due to patient fears of potential side effects of						
	treatment						
m.	1 ,						
n.	Is difficult due to lack of scientific evidence of survival						
0.	benifit Is difficult due to lack of consensus regarding screening						
•	guidelines						
p.	Is something I do because the patient demands it						
q.	Helps reduce prostate cancer mortality in average risk						
r.	patients age 50 years and olderls difficult due to a lack of confidence in test accuracy		_	_		_	
	is amount due to a lask of communities in test accuracy						
0							
Socia	al Influences and Social Support						
<ol> <li>Does your practice have formal written guidelines for prostate cancer screening?</li> <li>Yes</li> <li>No</li> <li>Don't Know</li> </ol> 2. Does your practice have informal or unwritten guidelines or policies for prostate cancer screening?							
	☐ Yes ☐ No ☐ D	on't Know					
orga	se indicate whether you follow prostate cancer screening red nizations. ase ✓ all that apply)	commenda	tions from a	any of the	following		
	American Academy of Family Physicians (AAFP)  American Cancer Society (ACS)						
	use check (🗸) your opinion about how much each of the follow scourages your <b>current practices or beliefs about</b>	wing indivi	duals or en	tities enco	urages		
DRE							
	Stror		icoouraga	Noither	Encourage	Strongly	
a.	American Academy of Family Physicians	naye Di	iscourage	Neither	Encourage	Encourage	
	(AAFP)						

		Strongly Discourage	Discourage	Neither	Encourage	Strongly Encourage
b.	American Cancer Society (ACS)				Liteodrage	
c.	American College of Preventive Medicine (ACPM)					
d. e.	American College of Physicians (ACP)/ASIM American Urological Association (AUA)	□				
f.	United States Prevention Services Task Force (USPSTF)					
g. h.	Medical school attended/ residency training Professional organization(s) guidelines					
i.	Medical literature (e.g., JAMA, NEJM, Cochran Collaborative)Practice setting philosophy		_	_	_	_
j.	Practice setting philosophy					
k. I.	Community influences					
m.	experiences  Community practice standard					
n.	Patient or family requests					
0.	Other(Specify)					
PSA	Testing:	Strongly				Ctrongly
		Strongly Discourage	Discourage	Neither	Encourage	Strongly Encourage
a.	American Academy of Family Physicians (AAFP)		<b>_</b>			
b.	(AAFP) American Cancer Society (ACS)					
C.	American College of Preventive Medicine (ACPM)					
d.	American College of Physicians (ACP)/ASIM					
e. f.	American Urological Association (AUA) United States Prevention Services Task Force (USPSTF)					
g.	Medical school attended/ residency training	<u> </u>				
h.	Professional organization(s) guidelines					
i.	Medical literature (e.g., JAMA, NEJM, Cochran Collaborative)					
j.	Practice setting philosophy					
k. I.	Community influences  Personal practice experiences	<u>-</u>				
ı.	experiences		_	_	_	_
m.	Community practice standard	□				
n.	Patient or family requests	<b>_</b>				
0.	Other(Specify)					
Disc	ussing Prostate Cancer Screening:	Strongly				Strongly
		Discourage	Discourage	Neither	Encourage	Strongly Encourage
a.	American Academy of Family Physicians (AAFP)					
b.	American Cancer Society (ACS)	⊔				

		Strongly Discourage	Discourage	Neither	Encourage		rongly courage
c.	American College of Preventive Medicine						
٩	(ACPM)American College of Physicians (ACP)/ASIM						
d. e.	American Urological Association (AUA)			ō	ū		
f.	United States Prevention Services Task Force		_	_	_		_
	(USPSTF)						
g.	Medical school attended/ residency training						
h. i.	Professional organization(s) guidelines Medical literature (e.g., JAMA, NEJM, Cochran		ā	ă	ā		<u> </u>
1.	Collaborative)						
j.	Collaborative) Practice setting philosophy						
k.	Community influences						
l.	Personal practice experiences	⊔					
m.	experiences  Community practice standard						
n.	Patient or family requests		ā	ā			ā
0.	Other (Specify)						
	(-1, ))					_	
Phys	sician Perceptions and Behaviors						
	·					_	
1. For	the next set of questions, please indicate <b>how</b> often:						
	, ,,,						
2	Wives, partners, or significant others of your male	Neve	er Sometime	es Half t	he time	Usually	Always
a.	patients influence the men to come in for the screening						
	tests			[	<b>_</b>		
b.	Men provide information about their family history of	_	_	_	_	_	_
•	prostate cancer		u	l			Ц
C.	Your patients bring up prostate cancer related issues during their office visit			[	$\neg$		
d.	Your patients ask about the PSA test		ā	Ţ	<u></u>		ō
	You discuss the possible <i>benefits</i> of prostate-specific						
	antigen (PSA) screening with your age-appropriate			r	_		
f	patients before ordering the test You discuss the possible <i>risks</i> of PSA screening with			ι	J		ш
1.	your age-appropriate patients before ordering the test			[	_		
	You discuss diet and its possible link to prostate cance	r 🗖		[			
h.	Your patients bring up prevention related questions	_		,	_		_
	regarding prostate cancer		u	ι			Ц
ı.	Paying for the screening tests is an issue with your patients			[			
j.	Performing the digital rectal examination (DRE) is a		_	·	_	_	_
	barrier for your patients			[			
k.	You use educational tools or decision guides on						
	prostate cancer (pamphlets, anatomical models) to share with your patients			Γ	_		П
l.	You keep abreast of the scientific literature on prostate	<b>_</b>	_	,	_	_	_
	cancer			[	<b>_</b>		

Strongly

2. How	knowledgeable are your male patients concerning prostate cancer screening issues?  □ No knowledge at all				
	□ A little knowledge				
	☐ A moderate amount of knowledge				
	☐ A great deal of knowledge				
0 11					
3. HOW	knowledgeable are you on prostate cancer screening guidelines?  No knowledge at all				
	S .				
	□ A little knowledge				
	☐ A moderate amount of knowledge				
	☐ A great deal of knowledge				
Patie	nt Scenarios				
prostate	t few questions are about your management of prostate-specific antigen (PSA) screening for cancer in your primary practice site. Below we present you with hypothetical patients that we ask espond to. Please respond regardless of whether or not you may see these types of patients.				
	scenario 1: A 55 year old White male, who has no current prostate-related symptoms, with no story of prostate cancer and has no serious co-morbidities.				
1.	For this type of patient, I generally (Please ✓ only one):				
	Refer to a urologist for screening.				
	Order the PSA test without discussing the possible benefits and risks with the patient.				
	Discuss the possible benefits and risks of PSA screening with the patient, then recommend the				
	test.				
	Discuss the possible benefits and risks of PSA screening with the patient, then let him decide whether or not to have the test.				
	patient asks. Other:				
2.	If you offer the PSA test and the patient declines, would you try to persuade him to have the test?				
	☐ Yes ☐ No ☐ Don't Know				
3.	Approximately what percent of your patients with the above characteristics actually get a PSA test done in your practice? $\_$				
4.	Approximately what percent of your patients with the above characteristics have their blood work including PSA done <b>before</b> seeing you for a health maintenance exam?				

Patient scenario 2: A 45 year old African American male, who has no current prostate-related symptoms, with no family history of prostate cancer and has no serious co-morbidities.

1.	For this type of patient, I generally (Please ✓only one):				
	Refer to a urologist for screening.  Order the PSA test without discussing the possible benefits and risks with the patient.				
	Discuss the possible benefits and risks of PSA screening with the patient, then recommend the test.				
	Discuss the possible benefits and risks of PSA screening with the patient, then let him decide whether				
	or not to have the test.				
_	Discuss the possible benefits and risks of PSA screening with the patient, and then recommend against the test.				
	Do not order the PSA test or discuss the possible benefits and risks with the patient unless the patient				
	asks Other:				
	Guioi.				
2.	If you offer the PSA test and the patient declines, would you try to persuade him to have the test?				
	☐ Yes ☐ No ☐ Don't Know				
3.	Approximately what percent of your patients with the above characteristics actually get a PSA test done in your practice?%				
4.	Approximately what percent of your patients with the above characteristics have their blood work including PSA done <b>before</b> seeing you for a health maintenance exam?%				
	Patient scenario 3: A 50 year old male, who has no current prostate-related symptoms, who has a family history of prostate cancer and has no serious co-morbidities.				
1.	For this type of patient, I generally (Please ✓only one):				
	Refer to a urologist for screening.				
	Order the PSA test without discussing the possible benefits and risks with the patient.				
	Discuss the possible benefits and risks of PSA screening with the patient, then recommend the				
	Discuss the possible benefits and risks of PSA screening with the patient, then let him decide				
	whether or not to have the test.  Discuss the possible benefits and risks of PSA screening with the patient, and then recommend against the test.				
	Do not order the PSA test nor discuss the possible benefits and risks with the patient unless the patient asks				
	Other:				

_	
2.	If you offer the PSA test and the patient declines, would you try to persuade him to have the test?
	☐ Yes ☐ No ☐ Don't Know
3.	Approximately what percent of your patients with the above characteristics actually get a PSA test done in your practice?%
4.	Approximately what percent of your patients with the above characteristics have their blood work including PSA done <b>before</b> seeing you for a health maintenance exam?

## Thank you for your participation in this survey.

Comments:		